skip to content
Primary navigation

Inhaled Corticosteroids

Drug - Inhaled Corticosteroids

February 2018

Therapeutic area - Respiratory/Asthma


Preferred Nonpreferred
Asmanex Twisthaler (mometasone furoate) Alvesco (ciclesonide)
Flovent HFA (fluticasone propionate)
Flovent Diskus (fluticasone propionate) Armonair Respiclick (fluticasone propionate)
Pulmicort Flexhaler (budesonide) Asmanex HFA (mometasone furoate)
Pulmicort Respules (budesonide inhalation suspension) budesonide inhalation solution
Arnuity Ellipta (fluticasone furoate)
QVAR (beclomethasone)
QVAR Redihaler (beclomethasone)

Approval criteria

The following criteria applies to all nonpreferred inhaled corticosteroids:

  • Patient has a diagnosis of asthma AND
  • Patient has tried and failed a trial of two of the preferred products. Trials must be at least two weeks in duration of continuous daily use.

Note: Failure is defined as no improvement or worsening in asthma symptoms after at least two weeks of continued daily use of the inhaled corticosteroid.

Expected side effects of any agent within the class are not considered failure. Expected side effects include: 

  • bad taste
  • dysphonia
  • oropharyngeal candidiasis
  • cough
  • sore throat

See Grandfathering Criteria for patient-specific exceptions.

Quantity limit

One inhaler per month


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top